Advertisement
“We’re pleased to bring this product to market for the customers and patients who will benefit from this cost efficient alternative in the market place,” explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio of products in the Hospital segment.”
Advertisement
Dr. Reddy’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Important Safety Information:
What Important Information Should I Know About Bortezomib for Injection, 3.5 mg/Vial?
- Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy
- For intravenous use only. Do not administer Bortezomib for injection by any other route
- Bortezomib for injection retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with bortezomib and who have relapsed at least six months after completing prior bortezomib treatment. Treatment may be started at the last tolerated dose
- Bortezomib can cause fetal harm when administered to a pregnant woman
- Patients with hypersensitivity (not including local reactions) to bortezomib or boron. Reactions have included anaphylactic reactions
- Bortezomib for injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib products
- If you are or plan on being pregnant. Females of reproductive potential should avoid becoming pregnant while being treated with Bortezomib for injection because of potential risk to the fetus and should use effective contraception during treatment with Bortezomib for injection and for seven months following the final dose
- Males with female sexual partners of reproductive potential should not father a child and must use effective contraception during treatment with Bortezomib for injection and for four months following treatment
- Females should not breastfeed during treatment with Bortezomib for injection and for two months after treatment
Before taking Bortezomib for Injection, tell your doctor if you previously have had or currently do have:
- Preexisting symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy
- History of syncope, receiving medications known to be associated with hypotension, and are dehydrated which may increase risk of hypotension
- Are at risk factors for, or have existing heart disease
- Have high tumor burden, risk of tumor lysis syndrome
- Are pregnant or plan to be pregnant
- Are nursing
- If you are receiving dialysis
- Have moderate or severe hepatic impairment
- Are taking medications for diabetes
- Are using other prescription and non-prescription medications and/or dietary and herbal supplements
Call your doctor or get emergency help right away if you develop:
- Peripheral Neuropathy
- Hypotension
- Cardiac Toxicity
- Pulmonary Toxicity
- Posterior Reversible Encephalopathy Syndrome (PRES)
- Gastrointestinal Toxicity
- Thrombocytopenia
- Neutropenia
- Tumor Lysis Syndrome
- Hepatic Toxicity
- Thrombotic Microangiopathy
What are the most common side effects of Bortezomib for Injection, 3.5 mg/Vial?
- Nausea
- Diarrhea
- Thrombocytopenia
- Neutropenia
- Peripheral neuropathy
- Fatigue
- Neuralgia
- Anemia
- Leukopenia
- Constipation
- Vomiting
- Lymphopenia
- Rash
- Pyrexia
- Anorexia
- Dizziness
- Syncope
- Females of reproductive potential should avoid becoming pregnant while being treated with Bortezomib for injection. Females of reproductive potential must use contraception during treatment with Bortezomib for injection and for seven months following treatment
- Avoid breastfeeding while receiving Bortezomib for injection and for two months after last dose
- Avoid coadministration with medications that are strong CYP3A4 inducers
- Avoid dehydration due to risk of hypotension, gastrointestinal toxicity, tumor lysis syndrome – Patients should drink adequate fluids
